Method of promoting bone growth with hyaluronic acid and growth factors

• US 6,221,854 B1
• Filed: 07/26/1999
• Issued: 04/24/2001
• Est. Priority Date: 03/05/1996
• Status: Expired due to Term

• Current Assignee: Depuy Spine Incorporated (Johnson & Johnson)
• Original Assignee: Orquest, Inc. (Johnson & Johnson)
• Inventors: Radomsky, Michael
• Primary Examiner(s): FONDA, KATHLEEN KAHLER
• Application Number:
  US09/360,543
• Time in Patent Office: 638 Days
• Field of Search: 514/2, 514/54, 514/62, 536/53, 530/350, 623/16
• US Class Current: 514/54
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/715 Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
• CPC Class Codes: A61K 31/728 Hyaluronic acid
• CPC Class Codes: A61K 38/1825 Fibroblast growth factor [FGF]
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A bone growth-promoting composition is provided comprising hyaluronic acid and a growth factor. The composition has a viscosity and biodegradability sufficient to persist at an intra-articular site of desired bone growth for a period of time sufficient to promote the bone growth. Preferably hyaluronic acid is used in a composition range of 0.1-4% by weight and preferred growth factor is bFGF, present in a concentration range of about 10⁻⁶ to 100 mg/ml.

Claims

1. A method of treating diseased, injured or abnormal bone at an intra-articular site of desired bone growth comprising the step of applying to said site a composition comprising an effective amount of a mixture of hyaluronic acid and a growth factor sufficient to enhance bone growth rate and magnitude and having sufficient viscosity and biodegradability to persist at said site for a period of time sufficient to enhance said bone growth rate and magnitude.

2. A method according to claim 1 wherein said hyaluronic acid is uncrosslinked.

3. A method according to claim 1 wherein said hyaluronic acid in said composition comprises about 0.1-4% by weight of said composition.

4. A method according to claim 1 wherein said growth factor comprises bFGF.

5. A method according to claim 4 wherein said bFGF is present in a range of about 10⁻

6 to 100 mg/ml in said composition.